Latest Conference Coverage


Jeffrey Cohen, MD: The Success of Ofatumumab in Relapsing MS

Jeffrey Cohen, MD: The Success of Ofatumumab in Relapsing MS

April 28th 2020

The neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the findings of a new pooled-data analysis of ofatumumab from the phase 3 ASCLEPIOS I and II trials.


Risdiplam Demonstrates Significant Motor Milestones in Infants with Type 1 SMA

Risdiplam Demonstrates Significant Motor Milestones in Infants with Type 1 SMA

April 28th 2020

In addition to increased motor milestone achievement, the safety profile of risdiplam was consistent with that observed in previous studies, with no new safety signals identified.


Eptinezumab Improves Consecutive Migraine-Free Days, Shortens Migraine Duration

Eptinezumab Improves Consecutive Migraine-Free Days, Shortens Migraine Duration

April 27th 2020

These data on the preventive migraine treatment confirmed findings from previous studies, with eptinezumab not only reducing total migraine days, but elongating the duration of consecutive migraine-free days.


Epidiolex Has Safe, Consistent Profile Over Long-Term in Tuberous Sclerosis Complex

Epidiolex Has Safe, Consistent Profile Over Long-Term in Tuberous Sclerosis Complex

April 27th 2020

Treatment with CBD resulted in a significant number of patients with TSC reporting being “much” or “very much” improved on the Subject/Caregiver Global Impression of Change.


M. Scott Perry, MD: Clinical Experience With Fenfluramine in Dravet Syndrome

M. Scott Perry, MD: Clinical Experience With Fenfluramine in Dravet Syndrome

April 26th 2020

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed his experience with Zogenix’s investigational Dravet syndrome treatment in clinical trials and in the Expanded Access Program.


Optimizing Acute Migraine Care Improves Quality of Life and Reduces Disability

Optimizing Acute Migraine Care Improves Quality of Life and Reduces Disability

April 26th 2020

Data from the OVERCOME study of more than 20,000 respondents suggest that those whose acute migraine treatment was optimized according to the mTOQ had less disability and better quality of life.


Ofatumumab Displays Superiority to Teriflunomide in Relapsing MS

Ofatumumab Displays Superiority to Teriflunomide in Relapsing MS

April 25th 2020

Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.


M. Scott Perry, MD: Real-World Fenfluramine Data in Dravet Syndrome

M. Scott Perry, MD: Real-World Fenfluramine Data in Dravet Syndrome

April 25th 2020

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.


Rimegepant Shows Early Efficacy in Acute Migraine Treatment

Rimegepant Shows Early Efficacy in Acute Migraine Treatment

April 24th 2020

Biohaven’s acute migraine treatment rimegepant showed numerically significant differences from placebo on pain relief, with benefit as early as 15 minutes postdose.


Real-World Dravet Syndrome Data Suggest Fenfluramine Provides Benefit

Real-World Dravet Syndrome Data Suggest Fenfluramine Provides Benefit

April 24th 2020

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.


Post-Hoc Analysis Suggests Eptinezumab Effective for Migraine at Initial Dosing

Post-Hoc Analysis Suggests Eptinezumab Effective for Migraine at Initial Dosing

April 24th 2020

Data confirmed the prior results of the PROMISE-1 and PROMISE-2 studies, indicating the preventive effect on migraine with eptinezumab begins as early as day 1 post-infusion.


BTK Inhibitor SAR442168 Meets Multiple Sclerosis End Points in Phase 2b

BTK Inhibitor SAR442168 Meets Multiple Sclerosis End Points in Phase 2b

April 23rd 2020

The drug's impact on neuroinflammation and neurodegeneration in the brain and spinal cord are currently being explored.


Siponimod Shows Long-Term Benefit for Secondary Progressive MS

Siponimod Shows Long-Term Benefit for Secondary Progressive MS

April 23rd 2020

Five-year EXPAND study data suggest that Novartis’s S1P receptor modulator has sustained benefit and delays disability over long-term treatment in patients with SPMS.


Erenumab Improves Daily Functioning and Quality of Life

Erenumab Improves Daily Functioning and Quality of Life

April 23rd 2020

The Novartis agent showed significant reduction of migraine days in both the real-world TELESCOPE and PERISCOPE studies in patients with migraine.


Perampanel May Improve Insomnia in Patients With Epilepsy and Anxiety

Perampanel May Improve Insomnia in Patients With Epilepsy and Anxiety

April 22nd 2020

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.


Mary Rensel, MD: Transitioning to Shared Medical Appointments

Mary Rensel, MD: Transitioning to Shared Medical Appointments

April 2nd 2020

The director of Pediatric MS and Wellness programming at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine discussed the harsh realities of patients adopting a new treatment method.


Le Hua, MD: Siponimod in Secondary Progressive Multiple Sclerosis

Le Hua, MD: Siponimod in Secondary Progressive Multiple Sclerosis

March 25th 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.


Le Hua, MD: Subanalysis of the EXPAND Study of Siponimod in SPMS

Le Hua, MD: Subanalysis of the EXPAND Study of Siponimod in SPMS

March 24th 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.


Le Hua, MD: Considering Age in Multiple Sclerosis Treatment

Le Hua, MD: Considering Age in Multiple Sclerosis Treatment

March 19th 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the need to take age into consideration when managing a patient with MS, and how the thinking about the disease and age has shifted.


Le Hua, MD: Disease Duration and Age in MS

Le Hua, MD: Disease Duration and Age in MS

March 18th 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed the current thinking about the challenges of addressing multiple sclerosis in older patients.


Robert Glanzman, MD: Overview of CNM-Au8

Robert Glanzman, MD: Overview of CNM-Au8

March 17th 2020

The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.


Quick Access to EVT Centers for Acute Stroke Is Greatly Limited, Study Suggests

Quick Access to EVT Centers for Acute Stroke Is Greatly Limited, Study Suggests

March 12th 2020

Data suggests that access to endovascular thrombectomy centers within 15 minutes is limited to less than one-fifth of the population, pointing to a need for improved access and bypass methodologies.


Mary Rensel, MD: Integrating Shared Medical Appointments in MS

Mary Rensel, MD: Integrating Shared Medical Appointments in MS

March 11th 2020

The director of Pediatric MS and Wellness at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine describes her study on shared medical appointments and the intricacies of integrating them into the common care realm.


Carrie Hersh, DO, MSc: Measuring Progressive Multiple Sclerosis

Carrie Hersh, DO, MSc: Measuring Progressive Multiple Sclerosis

March 10th 2020

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, discussed the challenges of current measurements and the need to adjust the reading of progressive MS.


Tanuja Chitnis, MD: Consequences of Incomplete Recovery in MS

Tanuja Chitnis, MD: Consequences of Incomplete Recovery in MS

March 9th 2020

The director of the Partners Pediatric MS Center at Massachusetts General Hospital for Children provided insight on the consequences of incomplete relapse recovery in multiple sclerosis.


Carrie Hersh, DO, MSc: Addressing Progressive Disease in MS

Carrie Hersh, DO, MSc: Addressing Progressive Disease in MS

March 7th 2020

The assistant professor of neurology at the Lerner College of Medicine and neurologist at Luo Ruvo Center for Brain Health, both of Cleveland Clinic, spoke to the importance of preventing progression in MS and treating the non-inflammatory aspects of the disease.


Augusto Miravalle, MD: How Cladribine Sets Itself Apart in MS

Augusto Miravalle, MD: How Cladribine Sets Itself Apart in MS

March 6th 2020

The associate professor in the department of neurology at the University of Colorado and neurologist at Advanced Neurology of Colorado discussed the advantages of cladribine and details of the ongoing CLICK-MS study.


Endovascular Therapy Displays Similar Outcomes to Intravenous Thrombolysis

Endovascular Therapy Displays Similar Outcomes to Intravenous Thrombolysis

March 3rd 2020

When performed by itself, endovascular therapy had greater rates of intracranial hemorrhage compared to a combination of both endovascular therapy and intravenous thrombolysis.


CNM-Au8 Improves Visual Acuity in Patients With MS With Optic Neuropathy

CNM-Au8 Improves Visual Acuity in Patients With MS With Optic Neuropathy

March 2nd 2020

This included the first 34 participants from the VISIONARY-MS study, which is currently ongoing with the orally delivered suspension of clean-surfaced, faceted gold nanocrystals.

© 2024 MJH Life Sciences

All rights reserved.